New injection aims to tackle stubborn high cholesterol and triglycerides
NCT ID NCT07695597
First seen Jul 10, 2026 · Last updated Jul 23, 2026 · Updated 2 times
Summary
This phase 2 trial tests an investigational injection called SYH2070 in adults with mixed hyperlipidemia—a condition where both cholesterol and triglycerides are high. Participants must already be on stable statin therapy. The study compares three doses of SYH2070 against a placebo to see how well it lowers blood fat levels over 24 weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- SYH2070 injection
- What this could lead to
- If successful, this could provide a new injectable option to help control cholesterol and triglyceride levels in people with mixed hyperlipidemia.
- What could go wrong
- This is an early-phase trial with a small number of participants. The drug may not prove effective or could have side effects. Results may not apply to everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIXED HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Second Affiliated Hospital Zhejiang University School of Medicine
RECRUITINGHangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.